Moreover, asymmetric dimethylarginine, an endogenous competitive inhibitor of endothelial nitric oxide synthase, is often higher in kidney disease patients and impairs nitric oxide bioavailability, exacerbating vascular dysfunction [31]. This evidence concerns the gene NOS3 and kidney disorder.